Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions

Oncogene

Volumn 26, Issue 18, 2007, Pages 2574-2584

  Nanjundan, M ^a   Zhang, F ^a   Schmandt, R ^a   Smith Mccune, K ^b   Mills, G B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AML1; Ovarian cancers; Splicing

Indexed keywords

ACUTE MYELOID LEUKEMIA 1B PROTEIN; AMINO ACID DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CELL GROWTH; CELL IMMORTALIZATION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMING UNIT; DEREGULATION; EPITHELIUM CELL; EXON; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CELL; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN VARIANT; RNA TRANSCRIPTION; TRANSACTIVATION; WILD TYPE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; BASE SEQUENCE; BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONY-FORMING UNITS ASSAY; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYSTADENOCARCINOMA, SEROUS; EXONS; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; SURVIVAL RATE; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEINS;

EID: 34247338576     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210067     Document Type: Article

References (28)

1. Bae SC, Ogawa E, Maruyama M, Oka H, Satake M, Shigesada K et al. (1994). PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials. Mol Cell Biol 14: 3242-3252.
2. Bartel F, Taubert H, Harris LC. (2002). Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2: 9-15.
3. Berger R. (1997). Acute lymphoblastic leukemia and chromosome 21. Cancer Genet Cytogenet 94: 8-12.
4. Biggs JR, Zhang Y, Peterson LF, Garcia M, Zhang DE, Kraft AS. (2005). Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res 3: 391-401.
5. Dairkee SH, Ji Y, Ben Y, Moore DH, Meng Z, Jeffrey SS. (2004). A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics 5: 47.
6. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS. (2004). Association of E-cadherin and betacatenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 35: 663-669.
7. Fowler M, Borazanci E, McGhee L, Pylant SW, Williams BJ, Glass J et al. (2006). RUNX1 (AML-1) and RUNX2 (AML-3) cooperate with prostate-derived Ets factor to activate transcription from the PSA upstream regulatory region. J Cell Biochem 97: 1-17.
8. Fujioka T, Takebayashi Y, Kihana T, Kusanagi Y, Hamada K, Ochi H et al. (2001). Expression of E-cadherin and betacatenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep 8: 249-255.
9. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M et al. (2004). Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol 166: 85-95.
10. Harrington KS, Javed A, Drissi H, McNeil S, Lian JB, Stein JL et al. (2002). Transcription factors RUNX1/AML1 and RUNX2/Cbfa1 dynamically associate with stationary subnuclear domains. J Cell Sci 115: 4167-4176.
11. He DC, Nickerson JA, Penman S. (1990). Core filaments of the nuclear matrix. J Cell Biol 110: 569-580.
12. Inoue M, Ogawa H, Miyata M, Shiozaki H, Tanizawa O. (1992). Expression of E-cadherin in normal, benign, and malignant tissues of female genital organs. Am J Clin Pathol 98: 76-80.
13. Kirschnerova G, Tothova A, Babusikova O. (2006). Amplification of AML1 gene in association with karyotype, age and diagnosis in acute leukemia patients. Neoplasma 53: 150-154.
14. Levanon D, Bernstein Y, Negreanu V, Ghozi MC, Bar-Am I, Aloya R et al. (1996). A large variety of alternatively spliced and differentially expressed mRNAs are encoded by the human acute myeloid leukemia gene AML1. DNA Cell Biol 15: 175-185.
15. Liu YN, Lee WW, Wang CY, Chao TH, Chen Y, Chen JH. (2005). Regulatory mechanisms controlling human Ecadherin gene expression. Oncogene 24: 8277-8290.
16. Mikhail FM, Sinha KK, Saunthararajah Y, Nucifora G. (2006). Normal and transforming functions of RUNX1: a perspective. J Cell Physiol 207: 582-593.
17. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T et al. (1995). Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 23: 2762-2769.
18. Molinari E, Gilman M, Natesan S. (1999). Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J 18: 6439-6447.
19. Orban TI, Olah E. (2003). Emerging roles of BRCA1 alternative splicing. Mol Pathol 56: 191-197.
20. Robinson HM, Broadfield ZJ, Cheung KL, Harewood L, Harris RL, Jalali GR et al. (2003). Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia 17: 2249-2250.
21. Sun L, Vitolo M, Passaniti A. (2001). Runt-related gene 2 in endothelial cells: inducible expression and specific regulation of cell migration and invasion. Cancer Res 61: 4994-5001.
22. Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K et al. (1996). The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol 16: 3967-3979.
23. Whitley BR, Palmieri D, Twerdi CD, Church FC. (2004). Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells. Exp Cell Res 296: 151-162.
24. Yamagata T, Maki K, Mitani K. (2005). Runx1/AML1 in normal and abnormal hematopoiesis. Int J Hematol 82: 1-8.
25. Yamaguchi Y, Kurokawa M, Imai Y, Izutsu K, Asai T, Ichikawa M et al. (2004). AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J Biol Chem 279: 15630-15638.
26. Zaidi SK, Sullivan AJ, van Wijnen AJ, Stein JL, Stein GS, Lian JB. (2002). Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites. Proc Natl Acad Sci USA 99: 8048-8053.
27. Zeng C, McNeil S, Pockwinse S, Nickerson J, Shopland L, Lawrence JB et al. (1998). Intranuclear targeting of AML/CBFalpha regulatory factors to nuclear matrix-associated transcriptional domains. Proc Natl Acad Sci USA 95: 1585-1589.
28. Zhang YW, Bae SC, Huang G, Fu YX, Lu J, Ahn MY et al. (1997). A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol 17: 4133-4145.